Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03432858 · ClinicalTrials.gov registry record · Phase 4

Preoperative Antibiotics for Carpal Tunnel Release Surgery

A Phase 4 study of Carpal Tunnel Syndrome, sponsored by WellSpan Health.

Completed
Registry status
Phase 4
Development phase
184
Enrollment target
1
Study location

NCT03432858 is a Phase 4 study of Carpal Tunnel Syndrome that has completed, run by WellSpan Health. The registered enrollment target is 184 participants, below the 214-participant average among 21 other Carpal Tunnel Syndrome trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03432858, a Phase 4 study of Carpal Tunnel Syndrome, has completed, sponsored by WellSpan Health.

COMPLETED
Registry status
Phase 4
Development phase
184 participants
Enrollment target
1
Study location

Study Summary

This is a clinical trial to determine how effective antibiotics administered prior to endoscopic carpal tunnel release surgery are in preventing surgical site infections.

Conditions Studied

Interventions

  • DRUG Vancomycin
  • DRUG Cefazolin
  • DRUG Saline Solution

Study Locations (1)

Pennsylvania

  • WellSpan Surgery and Rehab Hospital - York

Trial Details

FieldValue
Enrollment Target 184 participants
Start Date 2018-05-17
Est. Completion 2020-12-14
Phase Phase 4

Sponsor

WellSpan Health

21 total trials

What the Registry Record Tells You About NCT03432858

The ClinicalTrials.gov registry entry for NCT03432858 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 214-participant average among 21 other Carpal Tunnel Syndrome trials with a reported enrollment target (14% lower). The listed sponsor is WellSpan Health, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carpal Tunnel Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Vancomycin is the first listed.

NCT03432858 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03432858 about?

NCT03432858 is a clinical study titled "Preoperative Antibiotics for Carpal Tunnel Release Surgery". This is a clinical trial to determine how effective antibiotics administered prior to endoscopic carpal tunnel release surgery are in preventing surgical site infections.

What is the current status of trial NCT03432858?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 184 participants. The study started on 2018-05-17. Estimated completion is 2020-12-14.

What conditions does trial NCT03432858 study?

This clinical trial studies the following conditions: Carpal Tunnel Syndrome.

What interventions are being tested in trial NCT03432858?

The interventions under investigation include: Vancomycin (DRUG), Cefazolin (DRUG), Saline Solution (DRUG).

Who is sponsoring clinical trial NCT03432858?

This trial is sponsored by WellSpan Health, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03432858 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Carpal Tunnel Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.